7 October 2019 - SMC recommendation based on results from four pivotal Phase 3 studies, UltIMMa-1, UltIMMa-2, IMMvent and IMMhance evaluating more than 2,000 patients with moderate to severe plaque psoriasis.

AbbVie today announced that the Scottish Medicines Consortium has published a positive detailed advice document, confirming that Skyrizi (risankizumab) is recommended for the treatment of moderate to severe psoriasis in adult patients who have failed to respond to conventional systemic therapies (including cyclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.

Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialisation globally.

Read AbbVie press release